SCHEMBL753158

SCHEMBL753158

O=Cc1cc(=O)c(OCc2ccccc2)c(C(=O)c2ccc(Cc3ccc(F)cc3)o2)o1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
POLB P06746 2/20 0.37
MAOA P21397 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAOB P27338 2/20 0.36
NR4A2 P43354 1/20 0.35
LMNA P02545 2/20 0.35
MAPK1 P28482 1/20 0.35
CASP3 P42574 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
SLC16A3 O15427 1/20 0.35
MEN1 O00255 1/20 0.35
GPR34 Q9UPC5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL755739 0.91 PTGER1 (0.38) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL16921615 0.91 PTGER1 (0.38) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL754394 0.88 MAPT (0.36) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL16921611 0.88 MAPT (0.36) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL752918 0.88 MAPT (0.43) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL16921603 0.87 SMN1; SMN2 (0.43) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL751907 0.87 PTGER1 (0.40) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL16921609 0.86 LOXL2 (0.44) PTGER1SMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL18590778 0.86 ALDH1A1 (0.37) PTGER1SMN1; SMN2MAPTPOLBMAOA
SCHEMBL753257 0.85 SMN1; SMN2 (0.39) PTGER1SMN1; SMN2MAPTL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2266958-B1 Antiviral agent SHIONOGI & CO (JP) 2017-03-15 EP disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
EP-3042894-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2016-07-13 EP disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-1422218-B1 ANTIVIRAL AGENT SHIONOGI & CO (JP) 2012-03-21 EP disclosed
EP-2181985-B1 Antiviral Agent SHIONOGI & CO (JP) 2011-10-26 EP disclosed
EP-2266958-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2010-12-29 EP disclosed
EP-2181985-A1 Antiviral Agent SHIONOGI & CO., LTD. (JP) 2010-05-05 EP disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT PTGER1 4133/4885SMN1; SMN2 3953/4885MAPT 4635/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI PTGER1 3786/4885SMN1; SMN2 3746/4885MAPT 4426/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI PTGER1 3786/4885SMN1; SMN2 3746/4885MAPT 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.